img
header banner

DISCOVER THE SCIENTIFIC PROGRAMME 

Welcome to the latest EBROW 2025 newsletter, 
we are excited to share the following information: 

open to the public conference
Association & Patient Programme
two of our headline talks
Late-Breaking Abstract Submission

OPEN TO THE PUBLIC CONFERENCE 
“DIALOGUE ON BRONCHIECTASIS”

We are delighted to invite you to the Open to the Public Conference: 
“Dialogue on Bronchiectasis”

📅 Saturday, February 22nd

⌚ 16:00 – 18:30
 📍  Sorbonne University International Conference Center (CICSU) or virtually

🌍  Language: French and English with simultaneous translation

This open to the public conference aims to raise awareness about the impact of bronchiectasis on patients, families and caregivers, while highlighting the French healthcare system's solutions for improved management.

Scientific Programme
REGISTRATION FOR HCPs
Registration for Patients

ASSOCIATION & PATIENT PROGRAMME

patient banner

We are proud to host the Association & Patient Programme in collaboration with
 European Lung Foundation 

 

The Patient Programme aims to promote greater awareness and understanding of Bronchiectasis, through bringing diverse voices and perspectives together in the fight against this disease.

 

📣 Share this important news with your patients and encourage them to participate!

 

🎟 Free registration – available for both onsite and virtual attendance.

👉 Find out more and register now

TWO OF OUR HEADLINE TALKS

We’re very proud to present this year’s Scientific Programme, 
now officially accredited

badge

Here are just some of the brilliant headline talks you can expect to see:


Prof. Bush

Imperial College and Royal Brompton Hospital

 

Bronchiectasis reversal in children - is it possible? 

  • The traditional definition of bronchiectasis is that it is irreversible; however, in children and even in adults, airway dilatation may sometimes reverse.

  • Although unproven, it is likely that early, aggressive treatment of airway dilatation is more effective when initiated in the early stages.

  • Regardless of whether airway dilatation is present, chronic airway neutrophilic inflammation and infection should be treated aggressively to minimize the risk of disease progression.

 

 

Prof. Shteinberg

Carmel Medical Center and the Technion, Haifa

 

Eosinophilic inflammation in bronchiectasis: more than just blood eosinophil count

  • As the aetiologies of bronchiectasis are variable, the inflammation in bronchiectatic airways is also variable.

  • About 20% of patients with bronchiectasis have eosinophilic inflammation.

  • Blood eosinophil count is an imperfect marker, so alternative ways of identifying individuals with eosinophilic inflammation are needed.

  • Therapies targeted at eosinophilic inflammation may benefit this subset of patients.


For more information about all of the great talks at EBROW: Scientific Programme

LATE-BREAKING ABSTRACT SUBMISSION

Our dedicated Poster Sessions give you the opportunity to share your work:

  • Display your poster in the dedicated poster area

  • Present your research

  • Q&A with the audience

 Additionally, you’ll get invaluable feedback from the faculty, including guidance around advancing your career towards becoming conference faculty yourself. 

Late-Breaking Abstract Window – 24th January  – 3rd February 2025

quick submission guidelines

MEDIA PARTNERs

We would like to extend our gratitude to our media partners.

lettre
lettre
lettre

STAY TUNED & VISIT OUR WEBSITE
bronchiectasis-eu.org

We are also on social media and we will be sharing

#EBROW25 information on 

img
img
img
img

ORGANISING SECRETARIAT


Address: 74 Boulevard d’Italie, 98000 MONACO
Phone number: +377 97 97 35 55

E-mail: info@bronchiectasis-eu.org

This email has been sent to: «Email»
Click here to unsubscribe from this newsletter >

.
.